The results are expected to have a wide impact on more than 30 million Americans who are battling genetic diseases caused by mutations in genes.
MILWAUKEE, WI (PRWEB) April 25, 2017
On April 24, 2017, the American Society of Gene & Cell Therapy (ASGCT) lifted the embargo on 785 abstracts in anticipation of the largest gene and cell therapy conference in the world.
Researchers and physicians will unveil the details behind the groundbreaking abstract data May 10-13, 2017 in Washington D.C. at the Marriott Wardman Park Hotel.
The results are expected to have a wide impact on more than 30 million Americans who are battling genetic diseases caused by mutations in genes. Gene and cell therapy are overlapping fields of biomedical research with the goals of repairing the direct cause of genetic diseases in the DNA or cellular population, respectively. This has resulted in an improved outlook for currently incurable genetic diseases, such as muscular dystrophy, sickle cell disease, cystic fibrosis, and hemophilia, among many others.
For additional information or to register for free media access, please visit. http://www.asgct.org/am17.
The American Society of Gene & Cell Therapy is the primary professional membership organization for gene and cell therapy. The Society's members are scientists, physicians, patient advocates, and other professionals. ASGCT's mission is to advance knowledge, awareness, and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease. For more information, visit http://www.asgct.org.